These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20861066)

  • 1. ICH guidelines: inception, revision, and implications for drug development.
    Wang T; Jacobson-Kram D; Pilaro AM; Lapadula D; Jacobs A; Brown P; Lipscomb J; McGuinn WD
    Toxicol Sci; 2010 Dec; 118(2):356-67. PubMed ID: 20861066
    [No Abstract]   [Full Text] [Related]  

  • 2. The Work of the Council for International Organizations of Medical Sciences (CIOMS) in Global Pharmacovigilance.
    Younus MM; Zweygarth M; Rägo L; Harrison-Woolrych M
    Drug Saf; 2020 Nov; 43(11):1067-1071. PubMed ID: 33034859
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance.
    Nakazawa T; Kurokawa M; Kimura K; Wakata A; Hisada S; Inoue T; Sagami F; Heidel SM; Kawakami K; Shinoda K; Onodera H; Kumagai Y; Ohno Y; Kawamura N; Yamazaki T; Inoue T
    J Toxicol Sci; 2008 Aug; 33(3):277-82. PubMed ID: 18670158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines.
    J Biol Stand; 1989 Jul; 17(3):203-12. PubMed ID: 2677013
    [No Abstract]   [Full Text] [Related]  

  • 5. How will the genotoxicity guidelines for pharmaceuticals be changed by the ICH agreement.
    Sofuni T
    J Toxicol Sci; 1996 Dec; 21(5):461-4. PubMed ID: 9035054
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revision of the ICH guideline on detection of toxicity to reproduction for medicinal products: SWOT analysis.
    Barrow P
    Reprod Toxicol; 2016 Sep; 64():57-63. PubMed ID: 27046733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contribution of explanatory notes. Efficacy of the ICH plan for international clinical development of a new drug].
    Husson JM
    Ann Pharm Fr; 1999 Mar; 57(2):153-60. PubMed ID: 10365472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes to ICH guideline M3: new and revised guidance on nonclinical safety studies to support human clinical trials and marketing authorization.
    Ledwith BJ; DeGeorge JJ
    Clin Pharmacol Ther; 2011 Feb; 89(2):295-9. PubMed ID: 21178992
    [No Abstract]   [Full Text] [Related]  

  • 11. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.
    Snodin DJ; Ryle PR
    BioDrugs; 2006; 20(1):25-52. PubMed ID: 16573349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Points to consider" regarding safety assessment of biotechnology-derived pharmaceuticals in non-clinical studies (English translation).
    Nakazawa T; Kai S; Kawai M; Maki E; Sagami F; Onodera H; Kitajima S; Inoue T
    J Toxicol Sci; 2004 Dec; 29(5):497-504. PubMed ID: 15729005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard protocols based on the ICH guidelines for reproductive and developmental toxicity studies: an international implementation.
    Horimoto M
    J Toxicol Sci; 1996 Dec; 21(5):451-5. PubMed ID: 9035052
    [No Abstract]   [Full Text] [Related]  

  • 14. International Conference on Harmonisation: guidance on Q1D bracketing and matrixing designs for stability testing of new drug substances and products; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jan; 68(11):2339-40. PubMed ID: 12532979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The international serious adverse events consortium.
    Holden AL; Contreras JL; John S; Nelson MR
    Nat Rev Drug Discov; 2014 Nov; 13(11):795-6. PubMed ID: 25359365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICH activities on biotech topics.
    Zorzi-Morre P
    Dev Biol Stand; 1999; 100():151-3. PubMed ID: 10616186
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Cooperation on Harmonisation of Technical requirements for Approval of Veterinary Medicinal Products (VICH); final guidance on " Safety studies for veterinary drug residues in human food: reproduction toxicity testing" (VICH GL22); availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jan; 67(3):603-5. PubMed ID: 12365425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact analysis of ICH S9 on non-clinical development of anticancer drugs.
    Bonelli M; Di Giuseppe F; Beken S
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):361-6. PubMed ID: 26232707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.